Structure of G protein-coupled receptor GPR1 bound to full-length chemerin adipokine reveals a chemokine-like reverse binding mode
PLOS Biology · 2024
DOI: 10.1371/journal.pbio.3002838 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2024. Verfasst von Aijun Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China. Hauptthemen laut MEDLINE: Chemokines, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Program, Science, Technology and Innovation Commission of Shenzhen Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chemerin is an adipokine with chemotactic activity to a subset of leukocytes. Chemerin binds to 3 G protein-coupled receptors, including chemokine-like receptor 1 (CMKLR1), G protein-coupled receptor 1 (GPR1), and C-C chemokine receptor-like 2 (CCRL2). Here, we report that GPR1 is capable of Gi signaling when stimulated with full-length chemerin or its C-terminal nonapeptide (C9, YFPGQFAFS). We present high-resolution cryo-EM structures of Gi-coupled GPR1 bound to full-length chemerin and to the C9 peptide, respectively. C9 insertion into the transmembrane (TM) binding pocket is both necessary and sufficient for GPR1 signaling, whereas the full-length chemerin uses its bulky N-terminal core for interaction with a β-strand located at the N-terminus of GPR1. This interaction involves multiple β-strands of full-length chemerin, forming a β-sheet that serves as a “lid” for the TM binding pocket and is energetically expensive to remove as indicated by molecular dynamics simulations with free energy landscape analysis. Combining results from functional assays, our structural model explains why C9 is an activating peptide at GPR1 and how the full-length chemerin uses a “two-site” model for enhanced interaction with GPR1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China.
- Dongguan Songshan Lake Central Hospital, Dongguan Third People's Hospital, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.
- Warshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China.
- The Chinese University of Hong Kong, Shenzhen Futian Biomedical Innovation R&D Center, Shenzhen, China.
ORCID-Profile: Richard D Ye
Förderung
- Shenzhen Science and Technology Program
- Science, Technology and Innovation Commission of Shenzhen Municipality
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Program
- China Postdoctoral Science Foundation
- Shenzhen-Hong Kong Cooperation Zone for Technology and Innovation
- Ganghong Young Scholar Development Fund
- Start-up funds from Dongguan Songshan Lake Central Hospital
Zitieren
APA
Liu, A., Liu, Y., Chen, G., Lyu, W., Ye, F., Wang, J., Liao, Q., Zhu, L., Du, Y., & Ye, R. D. (2024). Structure of G protein-coupled receptor GPR1 bound to full-length chemerin adipokine reveals a chemokine-like reverse binding mode. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002838
Vancouver
Liu A, Liu Y, Chen G, Lyu W, Ye F, Wang J, et al. Structure of G protein-coupled receptor GPR1 bound to full-length chemerin adipokine reveals a chemokine-like reverse binding mode. PLOS Biology. 2024. doi:10.1371/journal.pbio.3002838
BibTeX
@article{Liu2024,
author = {Liu, Aijun and Liu, Yezhou and Chen, Geng and Lyu, Wenping and Ye, Fang and Wang, Junlin and Liao, Qiwen and Zhu, Lizhe and Du, Yang and Ye, Richard D},
title = {Structure of G protein-coupled receptor GPR1 bound to full-length chemerin adipokine reveals a chemokine-like reverse binding mode},
journal = {PLOS Biology},
year = {2024},
doi = {10.1371/journal.pbio.3002838}
}
EUVIMED